485 related articles for article (PubMed ID: 25838185)
1. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
Carpenter PA; Kitko CL; Elad S; Flowers ME; Gea-Banacloche JC; Halter JP; Hoodin F; Johnston L; Lawitschka A; McDonald GB; Opipari AW; Savani BN; Schultz KR; Smith SR; Syrjala KL; Treister N; Vogelsang GB; Williams KM; Pavletic SZ; Martin PJ; Lee SJ; Couriel DR
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1167-87. PubMed ID: 25838185
[TBL] [Abstract][Full Text] [Related]
2. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ; Wolff D; Kitko C; Koreth J; Inamoto Y; Jagasia M; Pidala J; Olivieri A; Martin PJ; Przepiorka D; Pusic I; Dignan F; Mitchell SA; Lawitschka A; Jacobsohn D; Hall AM; Flowers ME; Schultz KR; Vogelsang G; Pavletic S
Biol Blood Marrow Transplant; 2015 Jun; 21(6):984-99. PubMed ID: 25796139
[TBL] [Abstract][Full Text] [Related]
3. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
4. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
Couriel D; Carpenter PA; Cutler C; Bolaños-Meade J; Treister NS; Gea-Banacloche J; Shaughnessy P; Hymes S; Kim S; Wayne AS; Chien JW; Neumann J; Mitchell S; Syrjala K; Moravec CK; Abramovitz L; Liebermann J; Berger A; Gerber L; Schubert M; Filipovich AH; Weisdorf D; Schubert MM; Shulman H; Schultz K; Mittelman B; Pavletic S; Vogelsang GB; Martin PJ; Lee SJ; Flowers ME
Biol Blood Marrow Transplant; 2006 Apr; 12(4):375-96. PubMed ID: 16545722
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
6. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials.
Pavletic SZ; Lee SJ; Socie G; Vogelsang G
Bone Marrow Transplant; 2006 Nov; 38(10):645-51. PubMed ID: 16980994
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Shulman HM; Kleiner D; Lee SJ; Morton T; Pavletic SZ; Farmer E; Moresi JM; Greenson J; Janin A; Martin PJ; McDonald G; Flowers ME; Turner M; Atkinson J; Lefkowitch J; Washington MK; Prieto VG; Kim SK; Argenyi Z; Diwan AH; Rashid A; Hiatt K; Couriel D; Schultz K; Hymes S; Vogelsang GB
Biol Blood Marrow Transplant; 2006 Jan; 12(1):31-47. PubMed ID: 16399567
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.
Pidala J; Kim J; Betts BC; Alsina M; Ayala E; Fernandez HF; Field T; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1074-82. PubMed ID: 25805300
[TBL] [Abstract][Full Text] [Related]
10. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
[TBL] [Abstract][Full Text] [Related]
11. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Jagasia MH; Greinix HT; Arora M; Williams KM; Wolff D; Cowen EW; Palmer J; Weisdorf D; Treister NS; Cheng GS; Kerr H; Stratton P; Duarte RF; McDonald GB; Inamoto Y; Vigorito A; Arai S; Datiles MB; Jacobsohn D; Heller T; Kitko CL; Mitchell SA; Martin PJ; Shulman H; Wu RS; Cutler CS; Vogelsang GB; Lee SJ; Pavletic SZ; Flowers ME
Biol Blood Marrow Transplant; 2015 Mar; 21(3):389-401.e1. PubMed ID: 25529383
[TBL] [Abstract][Full Text] [Related]
14. Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.
Pirsl F; Curtis LM; Steinberg SM; Tella SH; Katić M; Dobbin M; Hsu J; Hakim FT; Mays JW; Im AP; Pulanić D; Mitchell SA; Baruffaldi J; Masuch L; Halverson DC; Gress RE; Barsony J; Pavletic SZ
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1517-1524. PubMed ID: 27118572
[TBL] [Abstract][Full Text] [Related]
15. How I treat refractory chronic graft-versus-host disease.
Sarantopoulos S; Cardones AR; Sullivan KM
Blood; 2019 Mar; 133(11):1191-1200. PubMed ID: 30674472
[TBL] [Abstract][Full Text] [Related]
16. Ancillary and supportive care in chronic graft-versus-host disease.
Couriel DR
Best Pract Res Clin Haematol; 2008 Jun; 21(2):291-307. PubMed ID: 18503994
[TBL] [Abstract][Full Text] [Related]
17. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
18. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.
Introna M; Lucchini G; Dander E; Galimberti S; Rovelli A; Balduzzi A; Longoni D; Pavan F; Masciocchi F; Algarotti A; Micò C; Grassi A; Deola S; Cavattoni I; Gaipa G; Belotti D; Perseghin P; Parma M; Pogliani E; Golay J; Pedrini O; Capelli C; Cortelazzo S; D'Amico G; Biondi A; Rambaldi A; Biagi E
Biol Blood Marrow Transplant; 2014 Mar; 20(3):375-81. PubMed ID: 24321746
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
